What this study adds to our knowledge?
-The mortality rate was reported 4% in sofosbuvir/daclatasvir +
hydroxychloroquine + Pentoxifylline group and 32% in the
sofosbuvir/daclatasvir + hydroxychloroquine group.
-The mean hospitalization days were 7.02 vs. 10.83 in the
sofosbuvir/daclatasvir + hydroxychloroquine + Pentoxifylline group and
control group.
-Pentoxifylline increased the survival rate of hospitalized COVID-19
patients.
-Pentoxifylline plays a preventive role for COVID-related mortality and
morbidity such as ARDS.